Asthma  >>  roflumilast  >>  Phase 3
Welcome,         Profile    Billing    Logout  

7 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
roflumilast / Generic mfg.
FLASH, NCT00076076: The Study: A Study of Roflumilast Versus Placebo in Patients With Asthma (BY217/M2-023)

Completed
3
822
US, RoW
Roflumilast
AstraZeneca
Asthma
 
06/05
NCT00163475: Efficacy and Safety of Roflumilast Taken in the Morning or Evening in Patients With Stable Asthma (12 to 70 y) (BY217/M2-015)

Completed
3
511
Europe, RoW
Roflumilast
AstraZeneca
Asthma
08/05
08/05
NCT00163527: Efficacy and Safety of Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Asthma (12 to 70 y) (BY217/M2-013)

Completed
3
2054
US, Europe, RoW
Roflumilast
AstraZeneca, Pfizer
Asthma
11/05
11/05
APTA-2217-07, NCT00246922: Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 71 y)

Completed
3
150
Japan
Roflumilast
AstraZeneca, Mitsubishi Tanabe Pharma Corporation
Bronchial Asthma
01/07
10/07
2004-001065-18: Morning versus evening administration of 500µg Roflumilast once dailyfor 6 weeks in patients with asthma.

Ongoing
3
60
Europe
Roflumilast,
ALTANA Pharma AG
Asthma
 
 
NCT00073177: Efficacy and Safety of Roflumilast in Patients With Asthma (BY217/M2-012)

Completed
3
819
US, RoW
Roflumilast
AstraZeneca
Asthma
 
 
NCT00242307: Efficacy and Safety of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 70 y) (APTA-2217-05)

Completed
2/3
450
Japan
Roflumilast
AstraZeneca, Mitsubishi Tanabe Pharma Corporation
Bronchial Asthma
09/06
06/07

Download Options